A few centimeters of the mouth in the patient's body, bleeding less than 100 ml, can successfully complete a minimally invasive heart surgery within two hours, and is completed under the premise of the heart. This was enough to be an incredible miracle a few years ago, but it has become a reality in today's high-tech. Robotics has enabled doctors to break through the limitations of the human eye. Through robotic surgery, the patient's trauma can be minimized and the accuracy of the surgery is raised to a whole new level.
As a leader in assisted medical robots for abdominal surgery, Intuitive Surgical (NASDAQ: ISRG) is the world's most advanced medical robot, the DaVinciSurgical System. As the earnings report released after the market on July 22 exceeded market expectations, the intuition surgery company's share price rose 17.7% to 461.63 US dollars the next day, the largest increase in the S&P 500 index. Since its inception in 2000, Intuition Surgery has been the darling of Wall Street institutions, and its share price has risen more than 70 times in more than a decade.
Market optimistic about new product sales
On July 22, the second quarter earnings report released by Intuition Surgery showed that the company's quarterly profit fell to $104 million ($2.77 per share) from $159.1 million ($3.9 per share) a year ago. The company's quarterly revenue fell 11% year-on-year to $512.2 million, better than market expectations of $499 million.
In the second quarter, the Insect Surgery's star product DaVinci system shipped 96 units, which was less than the 143 units in the same period last year, but better than the 87 units in the first quarter. Market participants also noted that 50 of the 96 DaVinci systems shipped in the second quarter were the latest four-generation products (daVinciXi), which was approved by the US Food and Drug Administration (FDA) in April this year. .
After the release of the earnings report, Wall Street institutions have raised the investment rating of the Intuition Surgery Company. RaymondJames analysts said that the new product will make the long-term prospects of the intuitive surgery company better, upgrade its rating to "out of the market" and raise the target price to $500. Stifel analysts believe that under the new products, Intuition Surgery will maintain a sales growth rate of more than 10% in the next 3-5 years, and the profit growth rate will reach 15%-20%, and its rating will be upgraded to “ Buy" and raise the target price to $600.
Active Pharmaceutical Ingredients
Youth Biotech CO,. Ltd. , https://www.youtherb.com